That makes it less addictive than opioids, which were involved in about 70,000 overdose deaths for the year ending June 2024.

Vertex Pharmaceuticals' suzetrigine shows promising results in treating painful lumbosacral radiculopathy, but stock falls ...

Pain has really been out of favor in the industry up until very recently,” said John Mulcahy, SiteOne Therapeutics’ CEO. The ...

“Chronic abdominal pain is complex because it involves multiple mechanisms, including inflammation, altered gut motility, and heightened sensitivity of the nervous system,” Muttenhalter told IE. “The ...

Vertex Pharmaceuticals said on Thursday its experimental non-opioid drug met the main goal of a mid-stage study but did not ...

Mixed results from a study focused on lower back pain left analysts wanting as well as confused about Vertex's plans to forge ...

Congress passed the Non-Opioids Prevent Addiction in the Nation Act in 2022 so seniors on Medicare have access to non-opioid pain management medications.

Protections for pregnant and addicted women, championed by a Pioneer Valley politician, were included in a sweeping law ...

Vertex stock plummeted Thursday after the company's pain drug proved it's no better than a placebo in patients with lower back and hip pain. "People Don't Understand How Dangerous It Can Be ...

Vertex Pharmaceuticals’ investigational non-opioid analgesic suzetrigine failed to outperform placebo. Investors voiced their ...